Revolution Medicines looks to raise $230M in new public offering

After its IPO almost two and a half years ago, a California biotech is gathering up more financing.

Targeted oncology biotech Revolution Medicines put out word Tuesday that it opened up an underwritten public offering, originally slated to be worth $200 million before upsizing it to $230 million. It is...

Click to view original post